Xuanzhu Biopharma rises 1.9% on positive lung cancer drug data

Xuanzhu Biopharma-B (02575.HK) announced its lung cancer treatment, DiLuoAke, showed significant efficacy in a Phase III study, boosting shares 1.9 percent.

The company presented the findings for the first-line treatment of ALK-positive advanced non-small cell lung cancer (NSCLC) in an oral session at the 2026 American Association for Cancer Research Annual Meeting.

The data demonstrated what the company called "statistically significant and clinically meaningful efficacy advantages." DiLuoAke, with the brand name Xuan Fei Ning, is a next-generation oral anaplastic lymphoma kinase (ALK) inhibitor. The stock rose HK$0.640 to close at HK$33.560. Specific data on response rates and safety were not detailed in the announcement.

The positive results move Xuanzhu Biopharma closer to potential regulatory approval, positioning it to compete in the lucrative market for ALK inhibitors. A successful launch could challenge established treatments and capture significant revenue, impacting the market share of current leaders in the NSCLC space.

DiLuoAke is an internally developed asset for Xuanzhu, and these results are a key milestone for its oncology pipeline. Investors will now watch for the company's filings with regulatory bodies like China's NMPA. The full data publication will be a key upcoming catalyst, providing critical details for comparison against existing ALK inhibitors.

This article is for informational purposes only and does not constitute investment advice.